Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis

  • 0Department of Hematology, Wuxi Branch of Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Wuxi, Jiangsu, China.

|

|

Summary

This summary is machine-generated.

Elevated soluble programmed death protein ligand-1 (sPD-L1) indicates a poorer prognosis for diffuse large B-cell lymphoma (DLBCL) patients, correlating with reduced overall survival and progression-free survival. Higher sPD-L1 is linked to more aggressive disease characteristics.

Area Of Science

  • Oncology
  • Immunology
  • Hematology

Background

  • Soluble programmed death protein ligand-1 (sPD-L1) significance in diffuse large B-cell lymphoma (DLBCL) prognosis is debated.
  • Previous analyses yielded conflicting results regarding sPD-L1's predictive value.

Purpose Of The Study

  • To investigate the prognostic impact of soluble PD-L1 (sPD-L1) expression in patients with DLBCL.
  • To clarify the association between sPD-L1 levels and patient survival outcomes.

Main Methods

  • A meta-analysis was conducted, searching major scientific databases (Web of Science, PubMed, Embase, CNKI) up to August 14, 2024.
  • Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for overall survival (OS) and progression-free survival (PFS).
  • Odds ratios (ORs) and 95%CIs were used to explore associations between sPD-L1 and clinicopathological factors.

Main Results

  • Seven studies involving 826 patients were included.
  • Elevated sPD-L1 was significantly associated with poor OS (HR = 2.81) and inferior PFS (HR = 3.16) in DLBCL patients.
  • Higher sPD-L1 correlated with poor ECOG PS, advanced clinical stage (III-IV), elevated LDH, and high IPI scores (3-5).

Conclusions

  • Higher sPD-L1 levels are a significant predictor of poor OS and PFS in DLBCL.
  • Elevated sPD-L1 is closely linked to aggressive disease factors in DLBCL, highlighting its potential as a prognostic biomarker.